5-Amino-1MQ Information & Coodination for Licensed U.S. Clinics
5-Amino-1MQ, also identified in FDA records as 5-amino-1-methylquinolinium and in a specific salt form as 5-amino-1-methylquinolinium iodide, is a small-molecule chemical compound that has been studied as an inhibitor of nicotinamide N-methyltransferase (NNMT).
Published research located for this page includes cell-based and animal studies. These findings do not establish an FDA-approved clinical use.
Phoenix Meds Inc. supports licensed U.S. healthcare organizations with clinic verification, documentation organization, access to publicly available regulatory information, and administrative review of pharmacy-related documentation.
Phoenix Meds is not a pharmacy, medical practice, manufacturer, prescriber, wholesaler, distributor, or dispensing entity.
What Licensed Clinics Should Know About 5-Amino-1MQ
5-Amino-1MQ has been studied as an inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme involved in nicotinamide metabolism.
Much of the published evidence surrounding 5-Amino-1MQ remains preclinical. For example, research evaluating metabolic effects has included cell and animal models rather than establishing an FDA-approved clinical use in humans.
For that reason, research findings should not be presented as established evidence that 5-Amino-1MQ is safe or effective for weight loss, metabolic optimization, fat reduction, energy enhancement, or other clinical outcomes.
The FDA substance record for 5-amino-1-methylquinolinium iodide identifies the chemical substance but does not itself establish regulatory approval.
Please review our medication resource page for information about clinic coordination.
Current FDA and Section 503B Considerations
FDA specifically addressed 5-amino-1-methylquinolinium iodide, identified in the warning letter as 5-Amino-1MQ, in a January 20, 2026 warning letter involving a registered outsourcing facility.
FDA stated that drug products compounded by that facility using 5-Amino-1MQ were not eligible for the exemptions provided under section 503B because 5-Amino-1MQ did not appear on the 503B Bulks List and was not being used to compound a drug appearing on FDA’s drug-shortage list.
FDA further stated that 5-Amino-1MQ was not eligible for the agency’s interim enforcement policy for certain bulk drug substances under section 503B in the circumstances described in that warning letter.
This FDA action concerned the section 503B framework and the facts described in the warning letter. It should not be rewritten as a blanket statement about every possible compounding pathway or factual situation.
Phoenix Meds does not represent 5-Amino-1MQ as FDA-approved or make product-specific determinations about whether a preparation qualifies for compounding under section 503A or section 503B.
Why Substance Identity Matters
FDA’s substance records distinguish 5-amino-1-methylquinolinium from specific salt forms such as 5-amino-1-methylquinolinium iodide. For professional review, clinics should identify the actual substance and formulation referenced in any documentation rather than relying only on the shorthand name “5-Amino-1MQ.” Relevant information may include:
- the identified chemical substance or salt form;
- formulation details;
- labeling;
- route of administration, where applicable;
- pharmacy or facility information; and
- supporting documentation associated with the specific preparation.
How Phoenix Meds Supports Licensed Clinics
Phoenix Meds helps licensed U.S. healthcare organizations manage the administrative side of professional documentation review.
For inquiries involving 5-Amino-1MQ, our support may include clinic credential verification, organization of available pharmacy or formulation documentation, access to publicly available FDA information, and administrative follow-up concerning documentation.
We can help clinic teams identify what information is available and what questions should be directed to the licensed pharmacy, prescriber, legal adviser, or other responsible professional.
Phoenix Meds does not determine whether 5-Amino-1MQ may lawfully be compounded, prescribed, dispensed, distributed, or used in a particular clinical setting.
Research and Evidence Considerations
5-Amino-1MQ has been investigated as an inhibitor of nicotinamide N-methyltransferase (NNMT). Published studies located for this page include laboratory and animal research, including studies involving cell systems and mouse models. These findings should not be interpreted as establishing an FDA-approved clinical use or as demonstrating safety or effectiveness for patients. Phoenix Meds does not claim that 5-Amino-1MQ:
- produces weight loss in patients;
- improves metabolic health;
- reduces body fat in humans;
- provides a clinically established non-stimulant alternative to approved therapies; or
- has established safety or effectiveness for human treatment.
Clinical interpretation of research findings belongs with appropriately qualified healthcare professionals.
Amino-1MQ Administrative Coordination for Licensed Clinics
Clinic Verification
Documentation Review
Licensed Parties
Frequently Asked Questions
Is 5-Amino-1MQ a peptide?
Is 5-Amino-1MQ FDA-approved?
The FDA materials reviewed for this page do not identify an FDA-approved drug product containing 5-Amino-1MQ.
FDA’s substance database contains records for 5-amino-1-methylquinolinium and related salt forms, but the existence of an FDA substance identifier or UNII does not itself mean that a drug product containing the substance has received FDA approval.
What has FDA said about 5-Amino-1MQ under section 503B?
In a January 2026 warning letter involving one outsourcing facility, FDA stated that drug products compounded using 5-Amino-1MQ were not eligible for section 503B exemptions because the substance was not on the 503B Bulks List and was not being used to compound a drug on the FDA shortage list.
That statement concerned the specific section 503B framework and circumstances described in the warning letter.
Does Phoenix Meds determine whether 5-Amino-1MQ may be compounded?
Does Phoenix Meds certify the quality or testing of 5-Amino-1MQ preparations?
What can Phoenix Meds help a licensed clinic with?
Important Notice
Phoenix Meds Inc. provides administrative coordination and documentation support for licensed U.S. healthcare organizations.
We are not a pharmacy, medical practice, manufacturer, wholesaler, distributor, prescriber, or dispensing entity.
Information on this page is intended for professional informational purposes. It is not medical advice, a prescribing recommendation, FDA approval, or a determination that a particular 5-Amino-1MQ preparation is available, eligible for compounding, safe, effective, or clinically appropriate.